|Mr. Martin J. Driscoll||Pres, CEO & Director||618.5k||N/A||1959|
|Dr. Radhakrishna P. Iyer||Co-Founder & Chief Scientific Officer||459.2k||N/A||1950|
|Dr. Nezam H. Afdhal||Chief Medical Officer||465.5k||N/A||1957|
|Mr. Jonathan P. Freve CPA, CPA||CFO & Treasurer||N/A||N/A||1978|
|Mr. Donald Mitchell MBA||VP of Operations & Corp. Devel.||N/A||N/A||N/A|
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV; a research agreement with The National Institute of Allergy and Infectious Diseases to evaluate HBV antisense oligonucleotide compounds; and a collaborative research agreement with the University of Texas Southwestern Medical Center for the evaluation of STimulator of INterferon Gene antagonist compounds in autoimmune disease models. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Spring Bank Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.